<

EDISON INVESTMENT RESEARCH LIMITED (LON:KEFI) BerGenBio (BGBIO): AXLeration of data catalysts in 2021

Transparency directive : regulatory news

27/02/2021 08:00

Edison Investment Research Limited
BerGenBio (BGBIO): AXLeration of data catalysts in 2021

27-Feb-2021 / 07:00 GMT/BST


 

London, UK, 27 February 2021

 

 BerGenBio (BGBIO): AXLeration of data catalysts in 2021

BerGenBio (BGBIO) has made steady progress during 2020. Lead asset bemcentinib (oral, once a day, highly selective AXL inhibitor) reported encouraging efficacy data from ongoing Phase II trials. Multiple catalysts expected in 2021 will define BGBIO's clinical trial strategy in AML/MDS and/or NSCLC. The FY20 operating loss was significantly higher than in FY19 (NOK261.1m vs NOK204.4m) due to higher set-up costs and increased investment in programme expenses. We expect operating expenses to increase significantly across 2021/22 as BGBIO further progresses its innovative AXL-centred pipeline, which includes bemcentinib in oncology (and COVID-19 potential) and the initiation of a Phase Ib/IIa trial to evaluate its AXL antibody tilvestamab in an undisclosed indication. BGBIO remains well funded following net c NOK700m raised in 2020. We value the company at NOK4.72bn or NOK54.1 per share.

 

We value BGBIO at NOK4.72bn or NOK54.1/share (NOK5.16bn or NOK59.1/share previously). Our forecasts remain unchanged, but our valuation has been affected by FX. The key value drivers are bemcentinib in second-line NSCLC (peak sales $1.2bn, NOK37.4/share) and AML (peak sales $598m, NOK12.3/share) plus the COVID-19 opportunity (peak sales $300m, NOK5.4/share). We do not include tilvestamab in our valuation, but will revisit this when we have clarity on the indications prioritised for development. 


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Dr Susie Jana +44 (0)20 3077 5700 healthcare@edisongroup.com

Dr John Priestner +44 (0)20 3077 5700 healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        https://www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1171534  27-Feb-2021 

fncls.ssp?fn=show_t_gif&application_id=1171534&application_name=news&site_id=symex


Other stories

28/03/2024 12:26
28/03/2024 14:30
28/03/2024 13:34
28/03/2024 12:08
28/03/2024 14:38
28/03/2024 13:20
28/03/2024 13:13
28/03/2024 13:47
28/03/2024 11:51
28/03/2024 13:48
28/03/2024 09:56
28/03/2024 09:33
28/03/2024 06:35
28/03/2024 07:06
28/03/2024 13:59
28/03/2024 09:59
28/03/2024 14:55
28/03/2024 14:57
28/03/2024 10:49
28/03/2024 12:35
27/03/2024 01:33
27/03/2024 17:00
28/03/2024 09:01
28/03/2024 14:27
28/03/2024 13:26
28/03/2024 09:50
28/03/2024 14:31
28/03/2024 13:10
28/03/2024 12:38
28/03/2024 10:02
27/03/2024 23:22
27/03/2024 21:46
27/03/2024 20:21
27/03/2024 20:12
28/03/2024 14:08
28/03/2024 13:25
28/03/2024 02:42
28/03/2024 07:33